Sepantronium hydrochloride
Based on 24 publication(s) in Google Scholar
Sepantronium hydrochloride (YM-155 hydrochloride) is a novel survivin suppressant with an IC50 of 0.54 nM for the inhibition of survivin promoter activity.
For research use only. We do not sell to patients.
- CAS No.: 355406-09-6
- Formula: C20H19ClN4O3
- Molecular Weight:398.84
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Sepantronium hydrochloride
More- Adv Sci (Weinh). 2025 Mar;12(12):e2409769. [Abstract]
- Cell Death Dis. 2020 Nov 15;11(11):982. [Abstract]
- Cancer Lett. 2018 Jul 1:425:54-64. [Abstract]
- Stem Cell Res Ther. 2020 Jun 10;11(1):229. [Abstract]
- Drug Deliv Transl Res. 2025 Oct 29. [Abstract]
- Mol Cancer Ther. 2025 Apr 28:OF1-OF13. [Abstract]
- Biochem Pharmacol. 2024 Jun:224:116242. [Abstract]
- Nutrients. 2018 Mar 15;10(3):353. [Abstract]
- Int Immunopharmacol. 2026 Apr 15:175:116421. [Abstract]
- Sci Rep. 2019 Aug 21;9(1):12149. [Abstract]
- Cancers (Basel). 2024 Sep 5;16(17):3090. [Abstract]
- Cancers (Basel). 2019 Oct 14;11(10):1550. [Abstract]
- Cancers (Basel). 2019 Jul 5;11(7):947. [Abstract]
- BMC Complement Med Ther. 2020 Sep 3;20(1):269. [Abstract]
- Cancer Res Commun. 2025 Jun 1;5(6):1034-1048. [Abstract]
- Toxicol Appl Pharmacol. 2020 Jun 15:397:115013. [Abstract]
- Anticancer Res. 2019 Sep;39(9):4817-4828. [Abstract]
- Anticancer Res. 2019 Feb;39(2):609-617. [Abstract]
- Anticancer Res. 2018 Dec;38(12):6699-6706. [Abstract]
- Biomed Pharmacother. 2026 Sep:202:119803.
- bioRxiv. 2026 May 1.
- bioRxiv. 2024 Aug 6:2024.03.21.586169. [Abstract]
- Res Sq. 2023 Dec 23:rs.3.rs-3770403. [Abstract]
- Research Square Preprint. 2021 Jul.
Customer Validation & Images
-
WB
-
Cell Imaging/Staining
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
IHC
Biological Activity
Description
IC50 & Target
IC50: 0.54 nM (survivin)
In Vitro
Sepantronium bromide (YM155; 30 μM) is not sensitive to survivn gene promoter-driven luciferase reporter activity. Sepantronium bromide shows significant supression on endogenous survivin expression in PC-3 and PPC-1 human HRPC cells with deficient p53 via transcriptional inhibition of the survivin gene promoter. Sepantronium bromide (100 nM) does not affect protein expression of c-IAP2, XIAP, Bcl-2, Bcl-xL, Bad, α-actin, and β-tubulin. Sepantronium bromide potently inhibits human cancer cell lines (mutated or truncated p53) such as PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5 and A375 with IC50s ranging from 2.3 to 11 nM, respectively[1].
Sepantronium bromide (YM155) resultin in an increase in sensitivity of NSCLC cells to γ-radiation. Sepantronium bromide combined with γ-radiation increases both the number of apoptotic cells and the activity of caspase-3. In addition, Sepantronium bromide delays the repair of radiation-induced double-strand breaks in nuclear DNA[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Sepantronium bromide (YM155) in combination with γ-radiation shows potent antitumor activity against H460 or Calu6 xenografts in nude mice[2].
In this orthotopic renal and metastatic lung tumors models, Sepantronium bromide (YM-155) and IL-2 additively decreases tumor weight, lung metastasis, and luciferin-stained tumor images[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 355406-09-6
-
Appearance Solid
-
Molecular Weight 398.84
-
Formula C20H19ClN4O3
-
Color Light brown to brown
-
SMILES
O=C(C1=C2[N+](CC3=NC=CN=C3)=C(C)N1CCOC)C4=C(C=CC=C4)C2=O.[Cl-]
-
Synonyms
YM-155 hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (24)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Chromosome Missegregation Triggers Tumor Cell Pyroptosis and Enhances Anti-Tumor Immunotherapy in Colorectal Cancer. [Abstract]2025 Mar;12(12):e2409769. PMID: 39903759 -
Cell Death Dis
A small natural molecule CADPE kills residual colorectal cancer cells by inhibiting key transcription factors and translation initiation factors. [Abstract]2020 Nov 15;11(11):982. PMID: 33191401 -
Cancer Lett
Survivin-targeted drug screening platform identifies a matrine derivative WM-127 as a potential therapeutics against hepatocellular carcinoma. [Abstract]2018 Jul 1:425:54-64. PMID: 29608986
Sepantronium hydrochloride purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2018 Jul 1:425:54-64. [Abstract]
The cell model HepG2-Sur5P-EGFP-Sur3U was treated with Sepantronium bromide (YM155) at a final concentration of 100 nmol/ml. After 24 h later, the fluorescence strength of EGFP was recorded and the expression of Survivin was examined.
Sepantronium hydrochloride purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2018 Jul 1:425:54-64. [Abstract]
Huh-7 cell xenograft models were established by subcutaneously injection of 1 × 106 cells per mouse in 4 groups of nude mice (n = 5/group). After five intratumoral injections of Sepantronium bromide (YM155) at 3 mg/ml, the tumor volume was counted weekly.
Sepantronium hydrochloride purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2018 Jul 1:425:54-64. [Abstract]
Huh-7 cell xenograft models were established by subcutaneously injection of 1 × 106. cells per mouse in 4 groups of nude mice (n = 5/group). After five intratumoral injections of Sepantronium bromide (YM155) at 3 mg/ml. The xenografted tumors were weighed and compared.
Sepantronium hydrochloride purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2018 Jul 1:425:54-64. [Abstract]
Sepantronium bromide (YM-155, 3mg/mL)The xenograft tumor sections were examined by immunohistochemistry and TUNEL labeling. The expression levels of Survivin and the percentages of apoptotic cells in xenografted tumors were quantified within 5 high-power fields under microscope and showed in histograms.
-
Stem Cell Res Ther
Pulp stem cells with hepatocyte growth factor overexpression exhibit dual effects in rheumatoid arthritis. [Abstract]2020 Jun 10;11(1):229. PMID: 32522231 -
Drug Deliv Transl Res
Leveraging quantum chemical properties in transfer learning for predicting blood-brain barrier permeability of drugs. [Abstract]2025 Oct 29. PMID: 41160380 -
Mol Cancer Ther
Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth. [Abstract]2025 Apr 28:OF1-OF13. PMID: 40293279 -
Biochem Pharmacol
ONC212 enhances YM155 cytotoxicity by triggering SLC35F2 expression and NOXA-dependent MCL1 degradation in acute myeloid leukemia cells. [Abstract]2024 Jun:224:116242. PMID: 38679209 -
Nutrients
Glycycoumarin Sensitizes Liver Cancer Cells to ABT-737 by Targeting De Novo Lipogenesis and TOPK-Survivin Axis. [Abstract]2018 Mar 15;10(3):353. PMID: 29543705
Sepantronium hydrochloride purchased from MedChemExpress. Usage Cited in: Nutrients. 2018 Mar 15;10(3):353. [Abstract]
Influences of YM155, a chemical inhibitor of survivin on ABT-737-induced apoptosis are analyzed by western blot.
-
Int Immunopharmacol
A multi-omics R-loop-linked risk program highlights CKS2-positive proliferative tumor cells as drivers of glioma growth. [Abstract]2026 Apr 15:175:116421. PMID: 41763168 -
Sci Rep
Extracorporeal shock waves protect cardiomyocytes from doxorubicin-induced cardiomyopathy by upregulating survivin via the integrin-ILK-Akt-Sp1/p53 axis. [Abstract]2019 Aug 21;9(1):12149. PMID: 31434946 -
Cancers (Basel)
Molecular Insights into the Anticancer Activity of Withaferin-A: The Inhibition of Survivin Signaling. [Abstract]2024 Sep 5;16(17):3090. PMID: 39272948 -
Cancers (Basel)
Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs. [Abstract]2019 Oct 14;11(10):1550. PMID: 31614999 -
Cancers (Basel)
Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction. [Abstract]2019 Jul 5;11(7):947. PMID: 31284441 -
BMC Complement Med Ther
Myricanol 5-fluorobenzyloxy ether regulation of survivin pathway inhibits human lung adenocarcinoma A549 cells growth in vitro. [Abstract]2020 Sep 3;20(1):269. PMID: 32883260 -
Cancer Res Commun
Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells. [Abstract]2025 Jun 1;5(6):1034-1048. PMID: 40478628 -
Toxicol Appl Pharmacol
Arsenic trioxide-induced p38 MAPK and Akt mediated MCL1 downregulation causes apoptosis of BCR-ABL1-positive leukemia cells. [Abstract]2020 Jun 15:397:115013. PMID: 32305283 -
Anticancer Res
Brexpiprazole Reduces Survivin and Reverses EGFR Tyrosine Kinase Inhibitor Resistance in Lung and Pancreatic Cancer. [Abstract]2019 Sep;39(9):4817-4828. PMID: 31519584 -
Anticancer Res
2019 Feb;39(2):609-617. PMID: 30711936
Sepantronium hydrochloride purchased from MedChemExpress. Usage Cited in: Anticancer Res. 2019 Feb;39(2):609-617. [Abstract]
A2780 CSLCs are treated in the presence or absence of AS602801 (7.5 μM) and/or YM155 (10 nM) for 3 days, and then subjected to western blot analysis of survivin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
-
Anticancer Res
AS602801, an Anticancer Stem Cell Candidate Drug, Reduces Survivin Expression and Sensitizes A2780 Ovarian Cancer Stem Cells to Carboplatin and Paclitaxel. [Abstract]2018 Dec;38(12):6699-6706. PMID: 30504379 -
-
-
bioRxiv
2024 Aug 6:2024.03.21.586169. PMID: 38586030 -
Res Sq
Targeting mTOR and Survivin Concurrently Potentiates Radiation Therapy in Renal Cell Carcinoma by Suppressing DNA Damage Repair and Amplifying Mitotic Catastrophe. [Abstract]2023 Dec 23:rs.3.rs-3770403. PMID: 38196607 -
Purity & Documentation
References
[1]. Nakahara T, et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 2007 Sep 1;67(17):8014-21. [Content Brief]
[2]. Iisa T, et al. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res. 2008 Oct 15;14(20):6496-504. [Content Brief]
[3]. Guo K, et al. A combination of YM-155, a small molecule survivin inhibitor, and IL-2 potently suppresses renal cell carcinoma in murine model. Oncotarget. 2015 Aug 28;6(25):21137-47. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Sepantronium hydrochloride Related Classifications
HY-10194A Related Classifications
Powered by Bioz